Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The webpage has removed specific service availability notices and several past dates, indicating a shift in focus away from previous performance issues and updates.
    Difference
    1%
    Check dated 2025-02-24T22:39:54.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T15:28:52.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T10:49:21.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    The study has added detailed criteria for evaluating treatment response in patients with recurrent or progressive meningioma on pembrolizumab therapy, including definitions for progression-free survival (PFS) at 6 and 12 months, and overall survival (OS), while removing previous status updates and contact information.
    Difference
    28%
    Check dated 2025-01-27T04:56:08.000Z thumbnail image
  9. Check
    67 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-20T02:07:36.000Z thumbnail image
  10. Check
    75 days ago
    Change Detected
    Summary
    The website has updated the intervention type and status information, now listing it as 'Verified 2019-01 by Rabin Medical Center' and indicating the last known status as 'Recruiting', while also removing the previous principal investigator details.
    Difference
    2%
    Check dated 2025-01-12T22:48:44.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.